Silence Therapeutics said it has named Max Herrmann as its new CFO.
Herrmann was most recently CFO of Intercytex, a public company focused on regenerative medicine. Before that, he spent 10 years as a sell-side equity analyst, most recently at ING. He also previously served as financial controller for Onyx Pharmaceuticals.
He holds a degree in microbiology from the University of Kent.
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
